# Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

> **NCT00865098** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 27 (actual)

## Conditions studied

- Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00865098
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865098, "Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00865098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*